# MERMAID-1

Source: https://onco.cc/trials/mermaid-1/  
OnCo record `mermaid-1` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A lung cancer trial that planned to test whether adding the immunotherapy durvalumab to chemotherapy after surgery helps people whose blood shows leftover tumour DNA; the registry lists it as complete with 89 participants.

## Summary

MERMAID-1 was AstraZeneca's phase 3, double-blind trial of adjuvant durvalumab with platinum chemotherapy in completely resected stage II to III non-small-cell lung cancer, designed around ctDNA-detected minimal residual disease. The registry records a start on 17 July 2020, a status of completed and 89 participants, with primary and study completion on 31 August 2023. Together with MERMAID-2 it is the main example that a ctDNA-selected escalation trial can be hard to run in lung cancer, where adjuvant immunotherapy was approved for all-comers while the trials were recruiting.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-21
- Tags: ctdna-roadmap
- Registry id: NCT04385368
- Phase: 3
- Setting: Completely resected stage II to III non-small-cell lung cancer: adjuvant durvalumab plus platinum chemotherapy against placebo plus chemotherapy, with ctDNA-positive patients as the group of interest
- Sponsor: AstraZeneca
- Enrolled: 89

## Sources

- ClinicalTrials.gov NCT04385368: https://clinicaltrials.gov/study/NCT04385368

## Connected records

- trials: [MERMAID-2](https://onco.cc/trials/mermaid-2/)
- roadmaps: [ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment](https://onco.cc/roadmaps/ctdna-tests/)
- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- terms: [Circulating tumour DNA (ctDNA)](https://onco.cc/terms/ctdna/), [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/)

---
JSON: https://onco.cc/api/v1/entities/mermaid-1.json